PSMA radioligand therapy of prostate cancer.
PSMA radioligand therapy of prostate cancer.
Q J Nucl Med Mol Imaging. 2019 Jan 15;:
Authors: Beheshti M, Heinzel A, von Mallek D, Filss C, Mottaghy FM
Abstract
Defining an optimal therapeutic approach in metastatic castration-resistance prostate cancer (mCRPC) patients in advanced stages is still challenging in routine clinical practice. Prostate- specific membrane antigen (PSMA) targeted radionuclide therapy with β- or α-emitters such as 177-Lutethium (177Lu) or 225-Actinium (225A) has been a main focus at multiple academic researche centers in the last few years. This review article provides an overview of PSMA characteristics, clinical performance, safety and toxicity of PSMA targeted β- or α-radiation therapy.
PMID: 30644306 [PubMed - as supplied by publisher]
Source: Quarterly Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Tags: Q J Nucl Med Mol Imaging Source Type: research
More News: Academia | Cancer | Cancer & Oncology | Nuclear Medicine | Prostate Cancer | Radiation Therapy | Toxicology